期刊
MULTIPLE SCLEROSIS JOURNAL
卷 19, 期 9, 页码 1230-1233出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458513481395
关键词
Fingolimod; multiple sclerosis; CCR7; CSF; compartmentalized immune response
资金
- JSPS KAKENHI [23591236]
- Grant for the Promotion of Niigata University Research Projects
- Ministry of Health, Labour and Welfare of Japan (MN)
- Grants-in-Aid for Scientific Research [25893076, 23591236] Funding Source: KAKEN
Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor, and it traps lymphocytes in secondary lymphoid organs and precludes their migration into the central nervous system. We report the case of a patient who suffered a relatively severe relapse of multiple sclerosis (MS) during the initial 3 months of fingolimod therapy, with retention of CCR7 expression on CD4(+) T cells in the cerebrospinal fluid (CSF) despite decreased numbers of lymphocytes and decreased expression of CCR7 on CD4(+) T cells in the blood. These data suggest that fingolimod may cause differential effects on the CSF and blood lymphocytes of patients with MS during the initial months of therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据